Patents by Inventor Craig Stuart PACE

Craig Stuart PACE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics
    Patent number: 12012451
    Abstract: The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: June 18, 2024
    Assignee: The Rockefeller University
    Inventors: Craig Stuart Pace, David D. Ho
  • ENGINEERING PH-DEPENDENT ANTIGEN BINDING ACTIVITY INTO ANTI-HIV ANTIBODIES WITH IMPROVED PHARMACOKINETICS
    Publication number: 20210054054
    Abstract: The disclosure is directed to a histidine-mutated anti-HIV antibody having one or more mutations at the residue Y53a, D58, K96, D97, N98, or T100a in the heavy chain of ibalizumab, and at the residue S26, L30, L33, Q89, Y92, S93 or Y94 in the light chain of ibalizumab. In addition, the disclosure also is directed to two histidine mutated variants with two mutations, one with mutations at the residues Y53a and Y94, and the other with mutations at the residues D58 and L30 in the heavy and light chains of ibalizumab, respectively.
    Type: Application
    Filed: August 19, 2020
    Publication date: February 25, 2021
    Inventors: Craig Stuart PACE, David D. HO